This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Apricus Biosciences Announces Podium Presentation Of Femprox(R) Phase III Clinical Data At 2012 World Meeting On Sexual Medicine

SAN DIEGO, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) ( www.apricusbio.com) today announced a podium presentation titled, "Updated analyses of a randomized, double-blind, Phase 3 study of Femprox®, an alprostadil cream with a novel transdermal delivery technology (NexACT®) for the treatment of female sexual arousal disorder (FSAD)," will take place on Monday, August 27, 2012, at 4:30 p.m. CT, as part of the 2012 World Meeting on Sexual Medicine, which is being held August 26-30, 2012 in Chicago.

The presentation will discuss an updated analysis of the approximately 400-women Phase III clinical trial conducted by Apricus Bio to provide further evidence of the statistically significant efficacy and safety profile of Apricus Bio's investigational drug, Femprox® (topical alprostadil 0.4 % cream), for the treatment of FSAD in pre- and post-menopausal women.

The data will be presented by Dr. Irwin Goldstein, Director of Sexual Medicine at the Alvarado Hospital in San Diego, and a member of Apricus Bio's Femprox® Clinical Advisory Board. Dr. Goldstein is the Editor of The Journal of Sexual Medicine, a member of numerous sexual medicine societies, the author or co-author of approximately 260 peer-reviewed papers, and an expert in the area of women's sexual health.

About Femprox ®

Femprox® is an alprostadil-based 0.4% topical cream intended for the treatment of FSAD. Apricus Bio has completed nine clinical studies to date, including one, 98-patient Phase II study in the U.S. and a near 400-patient Phase III study in China.

It is the Company's understanding that no product is currently approved in the U.S. for FSAD, a persistent or recurring inability to attain, or maintain adequate sexual excitement, causing personal distress.

Femprox® exerts a local, relaxant effect on vulvar and clitoral blood vessels in women, leading to increased blood flow.  The resultant increase in lubrication and sensory feedback is believed to produce a clinically significant increase in sexual arousal in women with FSAD.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,751.39 +121.12 0.69%
S&P 500 2,108.57 +15.32 0.73%
NASDAQ 5,111.7330 +22.5270 0.44%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs